Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: clinical consequences

The use of anticoagulants in patients with cancer is challenging as several co-morbidities modifying pharmacokinetic (PK) parameters and significant drug-drug interactions with concomitant anti-neoplastic therapies may lead to PK variability resulting in increased risk of thrombosis or bleeding.Data on the management of patients with cancer-associated thrombosis (CAT) in real life are scarce since patients with cancer presenting with significant comorbidities tend to be excluded from large trials.

Source: Critical Reviews in Oncology Hematology - July 9, 2018 Category: Cancer & Oncology Authors: Audrey Bellesoeur, Audrey Thomas-Schoemann, Marie Allard, David Smadja, Michel Vidal, J érôme Alexandre, François Goldwasser, Benoît Blanchet Source Type: research